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Abstract
Background: Onchocerciasis and lymphatic filariasis (LF) are major filarial infections targeted for elimination in
most endemic sub-Saharan Africa (SSA) countries by 2020/2025. The current control strategies are built upon
community-directed mass administration of ivermectin (CDTI) for onchocerciasis, and ivermectin plus albendazole
for LF, with evidence pointing towards the potential for novel drug regimens. When distributing microfilaricides
however, considerable care is needed to minimise the risk of severe adverse events (SAEs) in areas that are
co-endemic for onchocerciasis or LF and loiasis. This work aims to combine previously published predictive risk
maps for onchocerciasis, LF and loiasis to (i) explore the scale of spatial heterogeneity in co-distributions, (ii)
delineate target populations for different treatment strategies, and (iii) quantify populations at risk of SAEs across
the continent.
Methods: Geographical co-endemicity of filarial infections prior to the implementation of large-scale mass treatment
interventions was analysed by combining a contemporary LF endemicity map with predictive prevalence maps of
onchocerciasis and loiasis. Potential treatment strategies were geographically delineated according to the level of
co-endemicity and estimated transmission intensity.
Results: In total, an estimated 251 million people live in areas of LF and/or onchocerciasis transmission in SSA, based
on 2015 population estimates. Of these, 96 million live in areas co-endemic for both LF and onchocerciasis, providing
opportunities for integrated control programmes, and 83 million live in LF-monoendemic areas potentially targetable
for the novel ivermectin-diethylcarbamazine-albendazole (IDA) triple therapy. Only 4% of the at-risk population live in
areas co-endemic with high loiasis transmission, representing up to 1.2 million individuals at high risk of experiencing
SAEs if treated with ivermectin. In these areas, alternative treatment strategies should be explored, including biannual
albendazole monotherapy for LF (1.4 million individuals) and ‘test-and-treat’ strategies (8.7 million individuals) for
onchocerciasis.
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Conclusions: These maps are intended to initiate discussion around the potential for tailored treatment
strategies, and highlight populations at risk of SAEs. Further work is required to test and refine strategies in
programmatic settings, providing the empirical evidence needed to guide efforts towards the 2020/2025 goals
and beyond.
Keywords: Filariasis, Onchocerciasis, Lymphatic filariasis, Loiasis, Severe adverse events, Ivermectin, DEC,
Albendazole, Mapping, GIS
Background
There are at least three filarial nematode diseases of
public health importance in sub-Saharan Africa (SSA),
namely, lymphatic filariasis (LF; caused in SSA by
Wuchereria bancrofti), onchocerciasis (caused by Oncho-
cerca volvulus), and loiasis (caused by Loa loa). Infection
with these parasites is responsible for significant morbid-
ity across the continent, causing elephantiasis, river
blindness, and eye worm, respectively [1–3]. Whilst loiasis
is not yet included within the World Health Organiza-
tion’s (WHO) list of neglected tropical diseases (NTDs),
LF and onchocerciasis are targeted by the WHO 2012
Roadmap on NTDs [4] for elimination in selected African
countries by 2020 using preventive chemotherapy. This
strategy is implemented through community-wide mass
drug administration (MDA), delivered yearly (and in some
cases twice yearly) to all at-risk populations until trans-
mission has been interrupted, combined with vector con-
trol measures where feasible [4].
Large-scale MDA programmes, implemented locally in
endemic communities but coordinated and supported re-
gionally, have been ongoing in Africa for over 25 years, first
for onchocerciasis [5] and since 2000 for LF [6]. These are
widely considered among the most successful and cost-
effective public health interventions ever launched [5, 7].
Nevertheless, there are important factors limiting their sus-
tainability, including the availability of effective drug regi-
mens that ensure a rapid interruption of transmission. For
onchocerciasis, ivermectin has been the only drug used for
MDA since Merck & Co. Inc. first announced its donation
to endemic countries in 1987 [8], whilst for LF the mainstay
treatment is a combination of either diethylcarbamazine
(DEC, donated by Eisai Co. Ltd) - in non-onchocerciasis
endemic areas - or ivermectin, given annually, plus alben-
dazole (donated by GlaxoSmithKline) [9]. Although rela-
tively safe and efficacious against microfilariae (mf, the
larval progeny stage), these regimens are not considered to
exert a powerful macrofilaricidal (adult stage killing) effect
on the long-lived adult worms. Instead, ivermectin has a
temporary sterilising effect on female O. volvulus [10] and,
in combination with albendazole, also on W. bancrofti
[11]). Thus in order to interrupt transmission, MDA must
be continued, at high levels of treatment coverage and ad-
herence [12], for at least as long as the duration of the
reproductive lifespan of the adult worms (ranging from 4 to
12 years for W. bancrofti [13] and from 9 to 11 years for O.
volvulus, with 95% of the worms ending reproduction by
the age of 13 to 15 years [14].
For filarial control programmes to be successful in
shorter timeframes, regimens that kill or irreversibly steril-
ise adult worms are required [15]. As an alternative to de-
veloping a new compound, it has been suggested that
simultaneous provision of triple drug therapy (IDA; iver-
mectin + DEC + albendazole) may improve LF microfilar-
ial clearance and further impact upon adult worms [16]. A
pilot study conducted in Papua New Guinea has reported
that single dose IDA treatment rapidly eliminated all W.
bancrofti mf from peripheral blood. Encouragingly, all par-
ticipants treated with this regimen remained amicrofilar-
aemic for at least 2 years following treatment, suggesting
sterilisation or killing of adult worms [16]. Recent simula-
tion modelling based on these findings has further sug-
gested that the triple-drug regimen has potential to
accelerate the elimination of LF, conditional on achieving
high population coverage and low systematic non-
adherence to MDA [17]. To appreciate fully the potential
of IDA for reducing the duration of MDA interventions
against LF, it is imperative that these findings be replicated
within larger trial settings.
Whilst IDA may help to accelerate the elimination of
LF, it is important to delineate the settings where its use
for MDA would be safe and appropriate [18]. One major
concern is the risk of severe adverse events (SAEs),
which can arise following microfilaricidal medication. In
the limited setting of the IDA pilot trial, adverse events
were more common in those treated with the triple ther-
apy, although no SAEs were recorded [16]. This may
have important implications for programme safety and
compliance. DEC cannot be used in areas where oncho-
cerciasis is present, because it induces a strong local in-
flammation in patients with ocular (O. volvulus) mf [19].
Similarly, providing ivermectin or DEC to those with
high Loa loa microfilarial loads has been associated with
SAEs, including neurological sequelae and fatal enceph-
alopathy [20, 21], precluding their use in forest areas
throughout much of central Africa [22]. This has led to
the recommendation that twice-yearly albendazole be
implemented together with distribution of long-lasting
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insecticidal nets for control of LF in L. loa co-endemic
areas [23]. Another aspect that may hamper the large-
scale implementation of IDA in only-LF endemic areas
is the risk for individuals migrating from onchocerciasis
endemic areas, a frequent occurrence in central African
countries. This risk could be mitigated somewhat by
obtaining information about the history of residence of
those individuals to be treated.
Unfortunately, albendazole alone does not kill O. volvu-
lus macro- or microfilariae [24], reducing the number of
potential strategies for the control and elimination of on-
chocerciasis in L. loa co-endemic areas. This is particularly
true in areas hypoendemic for O. volvulus, where the risk
of SAEs in individuals with loiasis outweighs the benefits
of deploying ivermectin MDA. Current guidelines, devel-
oped by the Mectizan® Expert Committee and the Tech-
nical Consultative Committee (MEC/TCC) of the African
Programme for Onchocerciasis Control (APOC) recom-
mend to test for L. loa infection and treat accordingly
(‘test-and-treat’ protocols) when areas to be treated with
ivermectin are suspected, or known to be endemic for lo-
iasis [25]. By this approach, the relatively small proportion
of L. loa-infected individuals at risk of SAEs (those with >
30,000 mf/ml) are identified and excluded from treatment
with ivermectin [20, 26]. This can be difficult to imple-
ment in practice as the current gold standard for L. loa
diagnosis (thick-smear microscopy) requires trained
personnel in a central laboratory, and so results are not
immediately available for decision-making.
These challenges have prompted two areas of research
that together comprise an enhanced ‘test and treat’ strat-
egy: novel diagnostics to enable rapid identification of
those with high levels of L. loa infection in the field in real
time [27–29]; and new filaricides to treat onchocerciasis
without affecting L. loa [30, 31]. If ongoing development
and field-testing are successful, L. loa-O. volvulus co-
infected individuals at risk of SAEs could be excluded dur-
ing ivermectin mass treatment campaigns, and instead
treated with an alternative filariacide such as doxycycline
[32]. Additionally, a new strategy based on fine scale-
mapping of loiasis in onchocerciasis co-endemic areas has
also been suggested to improve targeting, on the basis that
environmental changes and population movements may
have changed the epidemiological scenario depicted by
previous RAPLOA surveys [33].
To facilitate adoption of these innovative MDA drug
regimens, whilst ensuring the risk of SAEs is minimised,
we must pay careful consideration to the co-distribution
of these three filarial species. Large-scale surveys for
each species have been conducted across most endemic
areas in Africa, and geostatistical approaches have been
used to predict the geographical distribution and endem-
icity levels prior to control [34–36]. The extent of spatial
heterogeneity in co-distributions across the SSA region
however is less clearly defined. Building upon previous
work by Kelly-Hope et al. [37, 38], we present an initia-
tive to use available, single-species spatial predictions to
delineate co-distribution of these major filarial infections
across SSA, enabling enumeration of target populations
for different treatment schemes and quantification of
populations potentially at-risk of SAEs.
Methods
Developing filariases co-endemicity maps for sub-Saharan
Africa
The mapping sources used to identify co-endemic filarial
infection settings across the continent include contem-
porary maps of LF endemicity published by the WHO’s
Expanded Special Project for Elimination of Neglected
Tropical Diseases (ESPEN) and published predictive risk
maps for onchocerciasis [34, 39] and loiasis [36] pro-
duced by the African Programme for Onchocerciasis
Control (APOC). The latter are available together with
other epidemiological resources at www.ntdmap.org
[40]. Several pragmatic adjustments were made to better
adapt these pre-control predictive maps to the contem-
porary situation, as outlined below. In brief:
(i) The current-day distribution of LF endemicity was
obtained from the new NTD portal developed by
ESPEN [41] and from the Preventive Chemotherapy
and Transmission Control (PCT) databank [42].
According to WHO guidelines, programmatic
implementation units (IUs; typically correspond to
administrative areas such as districts) are declared as
endemic for LF when at least 1 adult (≥ 15-yr) in
100 surveyed has a positive circulating filarial
antigen (CFA) test or presents W. bancrofti mf in
peripheral blood [43]. For areas where endemicity
status was unavailable, we used a risk map of
predicted LF antigenaemia prevalence developed
using geostatistical modelling approaches [35].
Further details are given in Additional file 1: Text S1
and Figure S1.
(ii)For onchocerciasis, we combined two published
sources to generate an SSA-wide map.We used
gridded maps of predicted prevalence at 5 × 5 km
resolution continuous risk surface because, unlike LF,
MDA is not always delivered to an entire implementa-
tion unit; instead, the eligible population only includes
residents of communities considered at risk, namely
living in transmission zones [44, 45] within the imple-
mentation unit. The first source considered was a map
of the estimated prevalence of palpable nodules (oncho-
cercomata) prior to the implementation of control
interventions, developed for the region covered by
APOC.With the exception of foci where onchocercia-
sis has been deemed eliminated (see below) all areas
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with nodule prevalence > 5% (prior to the initi-
ation of control activities) were considered to re-
main endemic and targetable for control, based
on prevalence contour maps and likelihood of
sustained local transmission [34, 44]. For West
Africa, the region covered by the Onchocerciasis
Control Programme in West Africa (OCP), en-
demicity was classified on the basis of a predictive
map of microfilarial prevalence [39]. The oncho-
cerciasis foci considered by the WHO to have
been eliminated in certain foci in Mali, Senegal
(including the Gambia River Basin, Faleme River
Basin and Bakoye River Basin) [46, 47], Nigeria
[48], Sudan and Uganda [49–51] and were
masked out, although elsewhere transmission still
persists [52–56].
(iii) A gridded map of the estimated prevalence of
eye worm history (EWH), obtained by
interpolating rapid assessment procedure for Loa
loa (RAPLOA) survey data conducted in 11 loiasis
endemic countries, was used as an approximation
to loiasis prevalence as described in detail
elsewhere [36]. The resulting map was stratified
into three areas based on the empirical
relationship between prevalence of EWH and high
L. loa microfilarial loads (≥ 30,000 mf/ml; i.e. the
threshold above which ivermectin-induced SAEs
may be expected [26]), namely, ≥ 40% EWH
prevalence (high risk of SAEs), 20–40% EWH
prevalence (lower SAE risk, but enhanced post-
treatment monitoring required) and < 20% EWH
prevalence (negligible risk of SAEs) [26].
Filarial co-endemicity was explored at IU level, the sub-
national administrative level considered for MDA interven-
tions. A harmonized IU-level cartography was obtained
from Geoconnect (http://www.geoconnect.org/). Overlaid
maps were classified according to the co-endemicity classi-
fication shown in Table 1 and population estimates for
2015 produced using a gridded population density map for
2015 [57]. Filarial transmission is not usually associated
with large urban areas, and so urban areas (defined as areas
with population densities ≥ 1000 persons/km2) and peri-
urban areas (those with > 250 persons/km2 within a 15 km
distance from urban extension edge) were excluded. Other-
wise, our approach assumes that, unless interruption of
transmission has been confirmed, the boundaries for trans-
mission remain as they were pre-control, despite reduced
prevalence in areas receiving control.
All data processing was conducted using ArcGIS 10.3
(ESRI, Redlands, CA, USA) and R v3.3.3 software. Grid-
ded maps of filarial infections were combined to gener-
ate an output raster dataset of filarial co-endemicity.
Population estimates were extracted by overlaying a
gridded map of population density for 2015 [57] with
the co-endemicity reclassified map.
Results and discussion
The resulting maps and figures highlight substantial
within-country heterogeneity in the distributions of the
three filarial infections, suggesting that to achieve opti-
mal impact safely, tailored treatment strategies need to
vary between (and perhaps even within) existing IUs.
Suggested treatment strategies for each co-endemicity
setting are provided in Table 1.
Table 1 Potential mass drug administration (or test-and-treat) strategies according to the co-endemicity of filarial infections in Africa
Onchocerciasis Lymphatic
filariasis (LF)
Loiasis, based on EWHa
Non-endemic Low (< 20%) Moderate (20–40%)b High (≥ 40%)
Non-endemic Endemic DEC + ALB+IVM DEC + ALB+IVM IVM + ALB
Enhancedc
ATS: T&T
ALB (2/year) + ITN
ATS: T&T
Non-endemic – – – –
Endemic Endemic IVM + ALB IVM + ALB IVM + ALB
Enhanced
ATS: T&T
IVM + ALB +ITN (T&T)
Enhanced & MMd
ATS: T&T





aIf assessment of loiasis is based on thick-smear or CellScope Loa, the alternative treatment strategy (ATS) of Test & Treat (T&T) will exclude those with > 30,000
microfilariae/ml and will treat the remainder with ivermectin (IVM). Those excluded from IVM treatment can be offered doxycycline or albendazole twice a year
bRe-assessment (by RAPLOA or by parasitological methods) if distance to area with high EWH prevalence is below certain threshold (i.e. 10 km)
cThe term ‘Enhanced’ refers to post-treatment monitoring of severe adverse events (SAEs). For interruption of transmission, the duration of treatment (e.g. number
of rounds) will be determined in part by the level of pre-control LF and/or onchocerciasis endemicity. Treatment coverage (of the total population) should be at
least 65% for LF and 80% for onchocerciasis; non-adherence to treatment should be minimised
dEnhanced & MM (enhanced surveillance of potential loiasis-related SAEs and medical monitoring at the community for five day safter MDA treatment)
Abbreviations: ALB albendazole, ATS alternative treatment strategy, DEC diethylcarbamazine, EWH eye worm history, IVM ivermectin, ITN insecticide-treated nets,
LF lymphatic filariasis, MDA mass drug administration, RAPLOA rapid assessment procedure for Loa loa, SAE severe adverse event, T&T Test (for loiasis) and treat
those not at risk of SAEs (quantify L. loa microfilaraemia and treat those with < 30,000 mf/ml)
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Aggregating the resulting population estimates
(Additional file 1: Table S1) identifies 251 million
people living in areas of LF and/or onchocerciasis
transmission in SSA (see Additional file 1: Figure S2
for further details of the co-distributions of these two
filarial nematode species). Of these, 81 million indi-
viduals across the continent live in LF mono-endemic
areas and may be eligible for IDA (54% of whom live
in eastern Africa), suggesting that this strategy could
have a transformative impact across the region. A fur-
ther 90.1 million live in areas targetable for ivermec-
tin plus albendazole (LF endemic regions without
high L. loa). Together, these two regimens bring sub-
stantial additional benefits due to the wider antipara-
sitic efficacy of combined albendazole and ivermectin,
notably against strongyloidiasis, trichuriasis, enterobia-
sis and some epidermal parasitic skin diseases, includ-
ing scabies [58, 59]. Lastly, of these 90.1 million, 79.7
million live in LF-onchocerciasis co-endemic areas,
highlighting substantial opportunities for programme
integration.
Our estimates clearly differ from figures provided by
WHO on people requiring preventive chemotherapy in
2015 (PCT databank, WHO [60]). This may be ex-
plained by the alternative source of demographic data
used to generate estimates, and by a more precise de-
lineation of onchocerciasis endemic areas based on the
geostatistical models. However, it should also be noted
that figures for LF endemicity in Middle Africa should
be treated with some caution, due to recent
Sources: Esri, USGS, NOAA
Sources: Esri, USGS, NOAA
Loiasis + LF endemicity
under MDA
LF endemic + EWH 40%
LF endemic + EWH<40%
LF endemic + No loiasis
0 500250 Miles¹
Loiasis + Oncho endemicity
under CDTi (total/partially)
Oncho endemic +  EWH 40%
Oncho endemic + EWH<40%




Fig. 1 Maps displaying areas currently under MDA treatment (hatched areas) which are co-endemic for loiasis and lymphatic filariasis (a)
and loiasis and onchocerciasis (b). Abbreviations: CDTi, community directed treatment with ivermectin; EWH, prevalence of eye worm
history; LF, lymphatic filariasis; MDA, mass drug administration; Oncho, onchocerciasis
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observations of cross-reactivity of the immunochroma-
tographic (ICT) test used in LF mapping surveys to L.
loa infections [61–63]. As a result, some areas currently
considered endemic for LF in Middle Africa may
require re-evaluation, which may in turn lead to the
shrinkage of the LF endemicity map for this region.
In total, only 4% of the SSA population living in areas at
risk for onchocerciasis and/or LF live in high prevalence
loiasis areas, although a further 5.7% live in areas of mod-
erate transmission. Within high loiasis prevalence popula-
tions, we estimate between 197,000 and 1.2 million people
to be at risk of ivermectin-associated SAEs, considering a
Sources: Esri, USGS, NOAA
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Fig. 2 Suitable mass drug administration (MDA) and “Test & Treat” based schemes tailored to the type and level of co-endemicity of three major
filarial infections in sub-Saharan Africa. The chart graph shows the overall population that may potentially benefit from different MDA schemes.
Abbreviations: ALB, albendazole; DEC, diethylcarbamazine; E, enhanced post-treatment monitoring for rapid determination of potential loiasis-
related SAEs; IVM, ivermectin; ITN, insecticide-treated nets; MDA, mass drug administration; MM, medical monitoring at the community during
3–4 days after MDA; R, regular monitoring of drug effects on treated communities; SAE, severe adverse event
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Table 2 Estimates of populations living in areas endemic for three major filariases in Africa, which may be targeted with tailored
mass drug administration (MDA) schemes according to the level of co-endemicity of the filarial nematode species
Estimates of populations living in areas potentially targetable with different MDA schemes
IVM + ALB IVM IVM + ALB (E)a IVM (E)a ALB(2/year) + ITNa IVM + ALB + ITN (E + MM)a DEC + ALB + IVMb IVM (E + MM)a
Eastern Africa 8,413,869 20,963,598 – – – – 45,192,922 –
Burundi – 1,390,645 – – – – – –
Eritrea – – – – – – 104,459 –
Ethiopia 2,340,296 14,392,313 – – – – 1,161,307 –
Kenya – – – – – – 1,045,022 –
Madagascar – – – – – – 13,557,237 –
Malawi – 2,048,395 – – – – – –
Mozambique 493,510 742,771 – – – – 10,369,358 –
Rwanda – 38,195 – – – – – –
Uganda 1,426,558 2,174,834 – – – – 992,624 –
Tanzania 4,153,505 176,445 – – – – 10,262,625 –
Zambia – – – – – – 6,426,817 –
Zimbabwe – – – – – – 1,273,473 –
Middle Africa 17,259,697 18,580,670 7,040,636 2,498,132 1,381,558 6,636,062 4,154,028 1,741,016
Angola 225,104 5,670,871 – 111,473 323 2314 116,774 244,993
Cameroon 3,064,962 435,486 1,270,793 245,554 331,363 1,548,497 635,665 251,586
CAR 555,240 5358 681,391 3062 697,014 756,080 60,605 33,118
Chad 1,139,547 857,065 476,212 25,770 – 211,614 363,059 –
Congo 37,729 3026 101,911 5767 39,154 29,242 27,589 9924
DRC 12,237,115 11,608,864 4,483,037 2,104,428 222,533 3744,58 2,950,335 1,038,597
Equatorial Guinea – – 27,293 – 91,172 343,735 – –
Gabon – – – 2078 – – – 162,798
Northern Africa 3,045,672 3,046,221 509,869 18,858 19,263 208,310 4,688,564 8669
South Sudan 2,998,136 2,969,800 509,869 18,858 19,263 208,310 843,150 8669
Sudan 47,536 76,421 – – – – 3,845,414 –
Western Africa 50,942,788 23,619,598 3,563,101 724,325 – 21,278 26,738,452 72,050
Benin 1,821,021 1,847,795 – – – – 97,670 –
Burkina Faso 4,332,528 5,527,801 – – – – – –
Ghana 307,396 2,030,355 – – – – 84,886 –
Guinea 3,390,416 227,213 – – – – 1,461,344 –
Guinea-Bissau 176,095 – – – – – 524,123 –
Liberia 42,021 – – – – – 1,964,905 –
Mali 5,959,767 6758 – – – – 2,861,263 –
Mauritania – – – – – – 700,830 –
Niger 78,987 842,637 – – – – 4,837,755 –
Nigeria 25,275,083 10,052,102 3,563,101 724,325 – 21,278 7,974,187 72,050
Senegal 412,921 – – – – – 2,883,203 –
Sierra Leone 2,688,260 – – – – – 683,589 –
Togo – 2,670,471 – – – – – –
Côte d’Ivoire 6,458,292 414,466 – – – – 2,664,695 –
Grand total 79,662,026 66,210,087 11,113,605 3,241,315 1,400,822 6,865,650 80,773,966 1,821,736
aTest & Treat (measure Loiasis microfilaraemia load before treatment and exclude those with > 30,000 mf/ml)
bTriple therapy with DEC is not yet recommended in countries where onchocerciasis is endemic. Re-evaluation of current endemicity is now considered in
areas that were classified as hypoendemic by REMO mapping
Abbreviations: ALB albendazole, CAR Central African Republic, DEC diethylcarbamazine, DRC Democratic Republic of Congo, E enhanced post-treatment
monitoring for rapid determination of potential loiasis-related SAEs, IVM ivermectin, ITN insecticide-treated nets, MDA mass drug administration, MM
medical monitoring at the community during 3–4 days after MDA; SAE severe adverse even
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minimum and maximum prevalence of very high intensity
of loiasis infection (densities ≥ 30,000 mf/ml) of 2 and
12% respectively [26]). Further national estimates are pro-
vided in Table S2 of Additional file 1. It is noteworthy that
a third of the areas potentially at high risk of SAEs are
currently reported as being under MDA treatment for LF
and/or onchocerciasis (Fig. 1), according to data available
at the ESPEN portal [41]. This may have reduced the in-
tensity of loiasis transmission in these areas and conse-
quently, reduced the numbers at risk of SAEs in areas
under treatment. There is evidence of persistent high
transmission in loiasis endemic areas however, even after
several years of intensive community-directed treatment
with ivermectin (CDTi) [64].
Within these high loiasis areas, only a small proportion
of the population requiring MDA would be suitable for
targeting with twice-yearly albendazole (non-onchocercia-
sis endemic, LF endemic), confined primarily to
Cameroon, Democratic Republic of Congo (DRC) and
Central African Republic (CAR). The vast majority (close
to 8.7 million people) are predicted to live in areas with
onchocerciasis, where test-and-treat strategies are re-
quired (Fig. 2 and Table 2). Of these, 7 million also live in
areas potentially co-endemic for LF (not accounting for
possible over-diagnosis of LF in L. loa endemic areas).
Considering the heterogeneity of disease distributions
further, Fig. 3 highlights the median number of MDA
strategies required within countries and existing IUs.
Only six endemic countries require just one MDA strat-
egy, with the majority requiring up to four. For some
countries in Middle Africa (including CAR and DRC) up
to eight different strategies are indicated. Even within
implementation units, more than one MDA strategy is
suggested for just over half (1775/3564) of all endemic
units due to fine scale spatial heterogeneity of transmis-
sion, with 653 implementation units across SSA (primar-
ily in Cameroon, DRC, Chad, Congo and Nigeria)
potentially requiring between three and eight strategies.
These patterns are emphasised Additional file 1: Figures
S3 and S4, further demonstrating how patterns of co-
endemicity vary within very small geographical areas,
and how this information might guide the tailoring of
local treatment strategies.
These maps are intended to initiate discussion around
tailored treatment strategies, rather than to provide de-
finitive recommendations. In particular, suggested rec-
ommendations for each IU presented here do not
consider co-endemicity of other IUs, either in the same
or in neighbouring countries. This is particularly import-
ant when considering whether an IDA-based MDA strat-
egy is appropriate. It is notable that, when taking a
stricter approach of only implementing triple drug ther-
apy in countries non-endemic for onchocerciasis, the
population that would benefit drops to 23,107,838 living
across 6 countries.
Some important limitations should be acknowledged.
First, the maps have been built upon predictive models
using historic data. Each has an inherent degree of uncer-
tainty, and should, wherever possible, be validated by na-
tional survey data. For example, nodule palpation for
onchocerciasis can give false positive results in non-
endemic areas [65] and lack sensitivity in areas of low sen-
sitivity [66]. Nodule prevalence surveys were designed to
delineate areas to be treated, namely, those with a nodule
prevalence higher than 20% (indicative of at least mesoen-
demicity). Subsequently, for the purpose of elimination, it
was agreed that the treatment boundaries need to be ex-
panded to ensure that there remain no untreated oncho-
cerciasis foci that might pose a future threat of
reinfection. The nodule prevalence threshold below which
we can assume there is no onchocerciasis transmission is
still under discussion. Nevertheless, a 5% threshold has
been suggested on the basis of non-onchocercal ‘nodule’
prevalence around 2% in endemic areas [67]. Such as-
sumption will require further investigation.
Recent parasitological surveys have shown many areas
considered as hypoendemic no longer to be endemic [68].
Furthermore, as noted above some areas highly endemic
for loiasis in Middle Africa may require to be remapped
for LF due to potential cross-reactivity of the ICT cards.
Secondly, the onchocerciasis and loiasis estimates re-
flect disease distribution prior to the scale up of mass
treatment. Although efforts have been made to exclude
areas considered as having interrupted transmission, we
did not account for potential reduction on the intensity
of loiasis transmission due to successive MDA rounds
Fig. 3 Variety of MDA schemes by country and implementation
unit (IU) according to filariasis co-endemicity. The y-axis displays
the number of IUs in which 1 to 8 different MDA schemes would
be applicable according to the distribution and overlapping of
loiasis, onchocerciasis and lymphatic filariasis
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with ivermectin when estimating population potentially
at-risk of suffering SAEs. Lastly, the incidence of loiasis-
associated SAEs following ivermectin administration is
seen to vary substantially within co-endemic areas [69],
which points to the existence of other as yet unidentified
risk factors that require further exploration.
Conclusions
Substantial advances have been made towards the elim-
ination of onchocerciasis and LF in SSA [5, 6]. Despite
prolonged control activities however, many endemic
areas are still experiencing ongoing transmission. Taken
together with the risk of loiasis-related SAEs, issues of
efficacy and appropriateness for existing treatment strat-
egies remains of major concern. The work presented
here highlights settings suitable for innovative MDA reg-
imens and integrated control, which may help to address
these concerns. Further work is required to test new
strategies in programmatic settings, providing the empir-
ical evidence needed to guide efforts towards the 2020
goals and beyond.
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